U.S. FDA flags Dabur's Dadra plant for data integrity, contamination lapses
The U.S. drug regulator cited Dabur India's Dadra and Nagar Haveli facility for falsified records, a live bird in the raw materials warehouse, and unreliable microbiology testing. The findings raise export-quality concerns for the 140-year-old FMCG major's U.S. health portfolio.
U.S. FDA flagged Dabur India's Dadra and Nagar Haveli plant for data integrity, contamination and maintenance lapses, including falsified records, a live bird in the raw material warehouse, and unreliable microbiology testing, raising export-quality concerns for the FMCG major's U.S. health portfolio.